S&P 500   4,595.95 (+0.23%)
DOW   36,207.97 (+0.25%)
QQQ   391.41 (+0.25%)
AAPL   195.09 (+0.42%)
MSFT   372.95 (+0.54%)
META   330.82 (+1.30%)
GOOGL   134.80 (-1.56%)
AMZN   147.14 (+0.18%)
TSLA   242.24 (-0.16%)
NVDA   475.49 (+2.05%)
NIO   7.40 (-1.20%)
BABA   72.12 (-0.29%)
AMD   128.95 (+0.45%)
T   16.94 (-0.88%)
F   11.04 (+2.03%)
MU   74.81 (+1.58%)
CGC   0.75 (+3.85%)
GE   120.58 (+0.92%)
DIS   92.61 (+0.28%)
AMC   6.90 (+1.17%)
PFE   28.77 (+0.49%)
PYPL   58.93 (+0.77%)
XOM   99.20 (+0.79%)
S&P 500   4,595.95 (+0.23%)
DOW   36,207.97 (+0.25%)
QQQ   391.41 (+0.25%)
AAPL   195.09 (+0.42%)
MSFT   372.95 (+0.54%)
META   330.82 (+1.30%)
GOOGL   134.80 (-1.56%)
AMZN   147.14 (+0.18%)
TSLA   242.24 (-0.16%)
NVDA   475.49 (+2.05%)
NIO   7.40 (-1.20%)
BABA   72.12 (-0.29%)
AMD   128.95 (+0.45%)
T   16.94 (-0.88%)
F   11.04 (+2.03%)
MU   74.81 (+1.58%)
CGC   0.75 (+3.85%)
GE   120.58 (+0.92%)
DIS   92.61 (+0.28%)
AMC   6.90 (+1.17%)
PFE   28.77 (+0.49%)
PYPL   58.93 (+0.77%)
XOM   99.20 (+0.79%)
S&P 500   4,595.95 (+0.23%)
DOW   36,207.97 (+0.25%)
QQQ   391.41 (+0.25%)
AAPL   195.09 (+0.42%)
MSFT   372.95 (+0.54%)
META   330.82 (+1.30%)
GOOGL   134.80 (-1.56%)
AMZN   147.14 (+0.18%)
TSLA   242.24 (-0.16%)
NVDA   475.49 (+2.05%)
NIO   7.40 (-1.20%)
BABA   72.12 (-0.29%)
AMD   128.95 (+0.45%)
T   16.94 (-0.88%)
F   11.04 (+2.03%)
MU   74.81 (+1.58%)
CGC   0.75 (+3.85%)
GE   120.58 (+0.92%)
DIS   92.61 (+0.28%)
AMC   6.90 (+1.17%)
PFE   28.77 (+0.49%)
PYPL   58.93 (+0.77%)
XOM   99.20 (+0.79%)
S&P 500   4,595.95 (+0.23%)
DOW   36,207.97 (+0.25%)
QQQ   391.41 (+0.25%)
AAPL   195.09 (+0.42%)
MSFT   372.95 (+0.54%)
META   330.82 (+1.30%)
GOOGL   134.80 (-1.56%)
AMZN   147.14 (+0.18%)
TSLA   242.24 (-0.16%)
NVDA   475.49 (+2.05%)
NIO   7.40 (-1.20%)
BABA   72.12 (-0.29%)
AMD   128.95 (+0.45%)
T   16.94 (-0.88%)
F   11.04 (+2.03%)
MU   74.81 (+1.58%)
CGC   0.75 (+3.85%)
GE   120.58 (+0.92%)
DIS   92.61 (+0.28%)
AMC   6.90 (+1.17%)
PFE   28.77 (+0.49%)
PYPL   58.93 (+0.77%)
XOM   99.20 (+0.79%)

Evoke Pharma Stock Price, News & Analysis (NASDAQ:EVOK)

$1.21
-0.02 (-1.33%)
(As of 11:50 AM ET)
Compare
Today's Range
$1.20
$1.24
50-Day Range
$1.08
$1.39
52-Week Range
$0.92
$5.96
Volume
8,914 shs
Average Volume
23,473 shs
Market Capitalization
$4.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

EVOK stock logo

About Evoke Pharma Stock (NASDAQ:EVOK)

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

EVOK Stock Price History

EVOK Stock News Headlines

Evoke Pharma Inc EVOK
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Evoke Pharma Shares Rise on New Gimoti U.S. Patent
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Evoke Pharma: Q3 Earnings Insights
Evoke Pharma Reports Third Quarter 2023 Financial Results
Evoke Announces Appointment of Group President Cris Morton
7 Under-the-Radar Growth Stocks Ready to Make a Splash
See More Headlines
Receive EVOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/19/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EVOK
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Net Income
$-8,220,000.00
Net Margins
-176.93%
Pretax Margin
-176.93%

Debt

Sales & Book Value

Annual Sales
$4.30 million
Book Value
$1.22 per share

Miscellaneous

Free Float
2,949,000
Market Cap
$4.10 million
Optionable
Not Optionable
Beta
0.32
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. David A. Gonyer R.Ph. (Age 59)
    Co-Founder, CEO & Director
    Comp: $806.53k
  • Mr. Matthew J. D'Onofrio MBA (Age 53)
    Co-Founder, President, COO, Secretary & Treasurer
    Comp: $557.11k
  • Dr. Marilyn R. Carlson (Age 75)
    Chief Medical Officer
    Comp: $518.14k
  • Mr. Christopher Quesenberry
    Chief Commercial Officer - Gimoti (TM)














EVOK Stock Analysis - Frequently Asked Questions

How have EVOK shares performed in 2023?

Evoke Pharma's stock was trading at $2.68 at the beginning of the year. Since then, EVOK shares have decreased by 55.2% and is now trading at $1.2001.
View the best growth stocks for 2023 here
.

Are investors shorting Evoke Pharma?

Evoke Pharma saw a increase in short interest in November. As of November 15th, there was short interest totaling 22,500 shares, an increase of 54.1% from the October 31st total of 14,600 shares. Based on an average trading volume of 12,200 shares, the short-interest ratio is currently 1.8 days. Currently, 0.7% of the company's stock are short sold.
View Evoke Pharma's Short Interest
.

When is Evoke Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 19th 2024.
View our EVOK earnings forecast
.

How were Evoke Pharma's earnings last quarter?

Evoke Pharma, Inc. (NASDAQ:EVOK) released its earnings results on Thursday, November, 9th. The specialty pharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter. The specialty pharmaceutical company had revenue of $1.56 million for the quarter. Evoke Pharma had a negative net margin of 176.93% and a negative trailing twelve-month return on equity of 517.99%.

When did Evoke Pharma's stock split?

Evoke Pharma's stock reverse split before market open on Monday, May 23rd 2022. The 1-12 reverse split was announced on Monday, May 23rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of Evoke Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evoke Pharma investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Advanced Micro Devices (AMD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD) and Bed Bath & Beyond (BBBY).

Who are Evoke Pharma's major shareholders?

Evoke Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David A Gonyer and Matthew J D'onofrio.
View institutional ownership trends
.

How do I buy shares of Evoke Pharma?

Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:EVOK) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -